19. 22279 12/29/2011 8:36:44 PM
Preliminary COMPANY Valuation Considerations
Drivers of valuation
Equity and
Financing Markets Existence of Potential
Asset’s and Required Rates of New Products,
Attractiveness Return Business Lines or
Acquisitions
Historical Financial
Projected Financial
Performance and
Performance and Risk
Consistency
Valuation
Competitive Industry
Dynamics Trends
Selected Publicly
Discounted Cash Flow
Traded Companies
Precedent M&A Analysis
Analysis
Transactions Analysis
26. Vision for Positioning at Novartis
To have a consistent framework for
developing and launching Novartis
brands, which will offer superior
value and patient outcomes through
a differentiated, ownable and
sustainable position in the market.
28. CURRENT
ENVIRONMENT:
CLINICAL Multiple Points of Entry into the Hospital
for Patients with Diabetes
CHALLENGES
Elective
Outpatient
Emergency Surgical
Room Procedure
General Intensive Care/
Medical/Surgical Critical Care Unit
Unit
PREVALENCE GAPS IN IMPACT ON CONTINUUM SAFETY QUALITY JOINT LILLY
AND COSTS CARE OUTCOMES OF CARE CHALLENGES GUIDELINES COMMISSION RESOURCES
29. Rise of Television
and Easy Credit
1950s 1960s 1970s 1980s 1990s
Private and Confidential
30. Outsourced Manufacturing
to Japan and Hong Kong
1950s 1960s 1970s 1980s 1990s
Private and Confidential
32. Hypothesized Mechanism of
Action of Cymbalta
DPNP and Fibromyalgia: Brain
In the spinal cord, 5-HT and
NE are believed to act via
descending pain pathways to
reduce perception of pain by
dampening pain signals
ascending to the brain from Dorsal horn
the dorsal horn1
Peripheral
Nociceptor
Ascending pathway
Although the exact mechanism of the analgesic action of Cymbalta in Descending pathway
humans is unknown, it is believed to be related to potentiation of
serotonergic and noradrenergic activity in the central nervous system (CNS)2
Important Safety Information and full Prescribing Information, including Boxed Warning, provided at this presentation.
1. Woolf CJ. Anesthesiology. 2007;106:864-867.
2. Cymbalta full Prescribing Information.
33. How Do We Select an Antipsychotic Based on
the Concept of Treatment Effectiveness?
Risk
Benefit
Treatment
Effectiveness
34. How Do We Select an Antipsychotic Based on
the Concept of Treatment Effectiveness?
Patient
Acceptance
Risk
Benefit
Treatment
Treatment
Effectiveness
Effectiveness
38. Title
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
Lorem ipsum dolor sit amet, consectetur adipisicing elit
• Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
– Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
• Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
– Officia deserunt mollit anim id est laborum
Sed do eiusmod tempor incididunt ut labore et dolore magna
aliqua
• Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
• dolore au irure dolor in reprehenderit in voluptate velit e
Lorem ipsum dolor sit amet, consectetur adipisicing elit
39. Pie Chart
Title
Segment 1
Segment 2
Segment 3
Segment 4
Segment 5
Segment 6
40. Bar Graph
4.5
4
3.5
Series 1
3
Series 2
2.5 Series 3
2 Series 4
1.5 Series 5
1 Series 6
0.5
0
Category 1 Category 2
41. WE TURN EXPERTISE
INTO RESULTS
AN INTRODUCTION TO J.H. COHN
Month Day, Year
43. SECTION
LOREM IPSUM DOLOR SIT
AMET, CONSECTETUER ADIPISCING
ELIT
Dolore magna aliquam erat volutpat.
Ut wisi enim ad minim veniam, quis
nostrud exerci tation ullamcorper
suscipit lobortis nisl ut aliquip ex ea
commodo consequat PLACE PHOTO HERE
Duis autem vel eum iriure dolor in
hendrerit in vulputate velit esse molestie
consequat, vel illum dolore eu feugiat
nulla
Eros et accumsan et iusto odio dignissim
qui blandit
Luptatum zzril delenit augue duis dolore te feugait
nulla facilisi
Nam liber tempor cum soluta nobis eleifend option
congue nihil imperdiet
Typi non habent claritatem insitam; est usus legentis
in iis qui facit eorum
We turn expertise into results. 43
44. PROFILES
TEAM
PLACE PLACE PLACE PLACE PLACE
PHOTO PHOTO PHOTO PHOTO PHOTO
HERE HERE HERE HERE HERE
First, Last First, Last First, Last First, Last First, Last
Biography here Biography here Biography here Biography here Biography here
PLACE PLACE PLACE PLACE PLACE
PHOTO PHOTO PHOTO PHOTO PHOTO
HERE HERE HERE HERE HERE
First, Last First, Last First, Last First, Last First, Last
Biography here Biography here Biography here Biography here Biography here
We turn expertise into results. 44
45. CONTACT
THANK YOU
J.H. Cohn New York
1212 Avenue of the Americas
Seventh Floor
New York, NY 10036-1600
212.297.0400
Fax: 212.922.0913
info@jhcohn.com
www.jhcohn.com
We turn expertise into results. 45
49. Today’s plan
1 Title
2 Title
3 Title
4 Title
5 Title
50. Nested graduated circles
Tumsan ullum ing eugait in henim zzrilla facil exer iurerillaore
dolutat, core conse corem aliquisi
Group 1
Lorem ipsum
Group 2 Nos dolortis autpatincin vercilla
orem ad diamconum exer
Group 3 Tatem num veril ulla feugait do
dolums andit vel ipit nibh ercil
dolorer iustrud modit aut
Group 4 Amconse feugue dolobortisit
praessed enim del et, vel irilit
vulpute feugiat aut
Group 5
Nosto odit